Financial Performance - The company's operating revenue for Q1 2025 was RMB 287.34 million, a decrease of 11.54% compared to RMB 324.81 million in the same period last year[7]. - Net profit attributable to shareholders for Q1 2025 was RMB 41.12 million, a significant increase of 115.11% from a loss of RMB 272.22 million in the previous year[7]. - Basic and diluted earnings per share for Q1 2025 were RMB 0.05, a turnaround from a loss of RMB 0.36 per share in the previous year, representing an increase of 113.89%[7]. - The weighted average return on equity increased by 3.86 percentage points to 0.51% compared to -3.35% in the same period last year[7]. - The net profit attributable to shareholders of the listed company increased by 115.11% compared to the same period last year, primarily due to significant losses from the fair value changes of biological assets in the previous year[16]. - The total comprehensive income for Q1 2025 was CNY 40,352,525.89, compared to a total comprehensive loss of CNY 272,499,809.53 in Q1 2024[30]. - Operating profit for Q1 2025 was CNY 49,382,588.17, a turnaround from an operating loss of CNY 293,008,274.73 in Q1 2024[28]. Cash Flow and Assets - The net cash flow from operating activities was RMB 65.15 million, down 45.69% from RMB 119.95 million in the same period last year[7]. - Cash and cash equivalents decreased to CNY 676,571,156.45 as of March 31, 2025, from CNY 965,203,128.59 at the end of 2024, a decline of 29.9%[22]. - The company’s cash flow management remains a priority, with a significant reduction in cash reserves noted[22]. - The cash and cash equivalents at the end of Q1 2025 were $676,571,156.45, a significant decrease from $2,865,314,156.35 in Q1 2024, reflecting a decline of about 76.4%[34]. - The net increase in cash and cash equivalents for Q1 2025 was -$288,629,929.27, contrasting with a positive increase of $11,667,128.38 in Q1 2024[34]. - The impact of exchange rate changes on cash and cash equivalents in Q1 2025 was -$1,154,223.86, compared to -$2,795,727.79 in Q1 2024, showing an improvement of approximately 58.7%[34]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 48,730[18]. - The top ten shareholders hold a total of 22.30% of shares, with the largest shareholder, Feng Yuxia, owning 167,160,633 shares[18]. - The company has not identified any related party relationships among the top ten shareholders, except for known familial connections[19]. Business Operations and Strategy - The laboratory services business contributed a net profit of RMB -41.34 million, a decline of 96.47% year-on-year, primarily due to increased industry competition[11]. - The company plans to enhance its laboratory services and financial management strategies to improve profitability amid competitive pressures[9]. - The company plans to focus on expanding its market presence and enhancing R&D efforts in the upcoming quarters[27]. - The company signed new orders worth approximately RMB 430 million during the reporting period, with a backlog of orders amounting to approximately RMB 2.2 billion at the end of the reporting period[20]. Non-Recurring Items - Non-recurring gains and losses for the reporting period amounted to RMB 15.46 million, with significant contributions from government subsidies and financial asset management[10][13]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 25.66 million, an increase of 109.14% from a loss of RMB 280.67 million in the previous year[7]. - The non-recurring gains and losses totaled RMB 15,456,940.42, indicating significant impacts from various non-operating activities[14]. Costs and Expenses - Total operating costs for Q1 2025 were CNY 288,252,886.21, down from CNY 293,294,646.96 in Q1 2024, reflecting a reduction of 1.4%[27]. - R&D expenses for Q1 2025 amounted to CNY 23,027,883.99, slightly increasing from CNY 22,967,298.39 in Q1 2024[27]. - Other income for Q1 2025 was CNY 5,270,400.41, down from CNY 6,650,918.69 in Q1 2024[28]. - Investment income for Q1 2025 was CNY 1,235,855.96, a decline from CNY 6,972,038.25 in Q1 2024[28]. Market and Risk Awareness - The company emphasizes the need for investors to be aware of investment risks due to market environment changes and industry competition[20]. - The company has not reported any changes in the participation of major shareholders in margin financing and securities lending activities[20]. - The company did not apply new accounting standards or interpretations starting from 2025, indicating a stable accounting approach for the current reporting period[34].
昭衍新药(06127) - 2025 Q1 - 季度业绩